Literature DB >> 6221938

Effect of thymoxamine on the human pupil.

D A Lee, T J Rimele, R F Brubaker, S Nagataki, P M Vanhoutte.   

Abstract

The specificity of thymoxamine, an alpha-adrenoceptor antagonist was determined from in vitro organ bath studies using isolated preparations of canine saphenous and portal mesenteric veins. It was found that thymoxamine interacts mainly with postjunctional alpha-adrenoceptors. The miotic effects of topical thymoxamine hydrochloride were measured in normal human eyes using infrared pupillography. The effects of five different concentrations of thymoxamine were measured over time. Time-response and concentration-response relationships were calculated. The maximal pupillary response occurs at 60 min after instillation of the drug and has a half-life of 10 hr. The minimum effective concentration of thymoxamine is 0.01%, and the maximum effective concentration is 1.3%. Thymoxamine's properties could make it a clinically useful drug to diagnose angle-closure glaucoma, and also to reverse drug-induced mydriasis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221938     DOI: 10.1016/0014-4835(83)90103-3

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  4 in total

1.  Evaluation of the effect of thymoxamine solution 0.5% on mydriasis induced by ibopamine solution 1%.

Authors:  F Drago; A Dal Bello; V Marino; R Pisati; E Lodola; P Barbieri
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration.

Authors:  Joon Mo Kim; Ki Ho Park; Chan Yun Kim; Hwang Ki Kim; Tae-Woo Kim; Mo Sae Kim
Journal:  Jpn J Ophthalmol       Date:  2011-06-17       Impact factor: 2.447

3.  The effect of 0.5% thymoxamine on the pattern-onset electroretinogram.

Authors:  D A Thompson; N Drasdo
Journal:  Doc Ophthalmol       Date:  1989-05       Impact factor: 2.379

4.  Thymoxamine: a miotic for intraocular use.

Authors:  F Grehn; T Fleig; E Schwarzmüller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.